Novel insights into the role of interleukin-27 and interleukin-23 in human malignant and normal plasma cells

Nicola Giuliani, Irma Airoldi

Research output: Contribution to journalArticle

Abstract

Multiple myeloma is a monoclonal postgerminal center tumor that has phenotypic features of plasmablasts and/or plasma cells and usually localizes at multiple sites in the bone marrow. The pathogenesis of multiple myeloma is complex and dependent on the interactions between tumor cells and their microenvironment. Different cytokines, chemokines, and proangiogenic factors released in the tumor microenvironment are known to promote multiple myeloma cell growth. Here, we report recent advances on the role of 2 strictly related immunomodulatory cytokines, interleukin-27 (IL-27) and IL-23, in human normal and neoplastic plasma cells, highlighting their ability to (i) act directly against multiple myeloma cells, (ii) influence the multiple myeloma microenvironment by targeting osteoclast and osteoblast cells, and (iii) modulate normal plasma cell function. Finally, the therapeutic implication of these studies is discussed.

Original languageEnglish
Pages (from-to)6963-6970
Number of pages8
JournalClinical Cancer Research
Volume17
Issue number22
DOIs
Publication statusPublished - Nov 15 2011

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Novel insights into the role of interleukin-27 and interleukin-23 in human malignant and normal plasma cells'. Together they form a unique fingerprint.

  • Cite this